{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:21:45Z","timestamp":1761675705828},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T00:00:00Z","timestamp":1258588800000},"content-version":"vor","delay-in-days":322,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective<\/jats:italic>: To investigate human epididymis protein 4 (HE4) levels in transitional cell carcinoma (TCC) of the urinary system and its relationship with clinicopathological features.<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>: 102 patients with TCC, 60 with benign urinary diseases, and 60 healthy controls were included in this study. The HE4 levels were used to analyze different clinicopathologic characteristics and changes between pre\u2010 and postsurgical operation.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>: The HE4 level was significantly increased in patients with TCC compared to patients with benign urinary diseases patients (<jats:italic>P<\/jats:italic>&lt;0.01) and healthy controls (<jats:italic>P<\/jats:italic>&lt;0.01), and the level of HE4 in patients with superficial TCC (Tis Ta T1) was significantly higher than that of the benign urogenital group (<jats:italic>P<\/jats:italic>&lt;0.05)and healthy controls (<jats:italic>P<\/jats:italic>&lt;0.05). There was a significant difference between HE4 levels in patients before and after operation (<jats:italic>P<\/jats:italic>&lt;0.05). There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (<jats:italic>P<\/jats:italic>&gt;0.05). The HE4 level was also different between patients with a single tumor versus patients with multiple tumors. The area under the curves of HE4 is 0.821. The sensitivity and specificity of HE4 at a cutoff value of 45.7\u2009pM were 67.6 and 88.3%, respectively.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system. J. Clin. Lab. Anal. 23:357\u2013361, 2009. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcla.20329","type":"journal-article","created":{"date-parts":[[2009,11,20]],"date-time":"2009-11-20T08:02:58Z","timestamp":1258704178000},"page":"357-361","source":"Crossref","is-referenced-by-count":14,"title":["Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system"],"prefix":"10.1002","volume":"23","author":[{"given":"Zhu","family":"Xi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma","family":"LinLin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,11,19]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"113","article-title":"Etiology of bladder cancer","volume":"11","author":"Shirai T","year":"1993","journal-title":"Semin Urol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod45.2.350"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1530\/ror.0.0030086"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20020869"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205363"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.125"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(99)00035-9"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(99)00342-X"},{"key":"e_1_2_1_10_2","first-page":"6281","article-title":"Large\u2010scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer","volume":"60","author":"Hough CD","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_11_2","first-page":"5007","article-title":"Identification by cDNA microarray of genes involved in ovarian carcinogenesis","volume":"60","author":"Ono K","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.3.1176"},{"key":"e_1_2_1_13_2","first-page":"5895","article-title":"Genetic analysis of early\u2010 vs. late\u2010stage ovarian tumors","volume":"61","author":"Shridhar V","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E03-05-0279"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0409"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.11.039"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3924"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.040"},{"key":"e_1_2_1_19_2","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom I","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.18.6692"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)77182-2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1037154100"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1322.044"},{"key":"e_1_2_1_24_2","first-page":"1001","article-title":"Expression of human kallikrein 7(hK7\/SCCE) and its inhibitor antileukoprotease (ALP\/SLPI) in uterine endocervical glands and in cervical adenocarcinomas","volume":"12","author":"Tian X","year":"2004","journal-title":"Oncol Rep"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1996.tb00208.x"},{"key":"e_1_2_1_26_2","first-page":"2537","article-title":"Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level","volume":"55","author":"Zhang M","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.04.002"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.017"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2007"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.20329","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.20329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T19:56:52Z","timestamp":1699905412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.20329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1002\/jcla.20329"],"URL":"https:\/\/doi.org\/10.1002\/jcla.20329","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}